Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM)

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Villalba A.
  • Gonzalez-Rodriguez A.P.
  • Arzuaga-Mendez J.
  • Puig N.
  • Arguiñano J.M.
  • Jimenez M.
  • Canet M.
  • Teruel A.I.
  • Sola M.
  • Díaz F.J.
  • Encinas C.
  • Garcia A.
  • Rosiñol L.
  • Suárez A.
  • Gonzalez M.S.
  • Izquierdo I.
  • Hernández M.T.
  • Infante M.S.
  • Sánchez M.J.
  • Sampol A.

Grupos

Abstract

Tandem ASCT has been suggested as a valid approach to improve the prognosis of patients with MM and HR cytogenetic. In this observational, retrospective study, 213 patients with newly diagnosed MM and HR cytogenetic in 35 hospitals from the Spanish Myeloma Group underwent single or tandem ASCT between January 2015 and December 2019 after induction with VTD/VRD. HR cytogenetic was defined as having =1 of the following: del17p, t(4;14), t(14;16) or gain 1q21. More patients in the tandem group had R-ISS 3 and >1 cytogenetic abnormality at diagnosis. With a median follow-up of 31 months (range, 10–82), PFS after single ASCT was 41 months versus 48 months with tandem ASCT (p = 0.33). PFS in patients with del17p undergoing single ASCT was 41 months, while 52% of patients undergoing tandem ASCT were alive and disease free at 48 months. In conclusion, tandem ASCT partly overcomes the bad prognosis of HR cytogenetic. © 2022 Informa UK Limited, trading as Taylor & Francis Group.

Datos de la publicación

ISSN/ISSNe:
1042-8194, 1029-2403

LEUKEMIA & LYMPHOMA  TAYLOR & FRANCIS LTD

Tipo:
Article
Páginas:
3438-3447
PubMed:
36124538
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
0,741 SCImago ℠
Cuartil:
Q2 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Cytogenetic Analysis; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Retrospective Studies; Transplantation, Autologous; antibiotic agent; bortezomib; busulfan; carfilzomib; dexamethasone; lenalidomide; melphalan; phenytoin; thalidomide; adult; aged; antibiotic prophylaxis; Article; autologous stem cell transplantation; cancer patient; cancer prognosis; chromosome aberration; cytogenetics; female; follow up; high risk cytogenetics; human; induction chemotherapy; major clinical study; male; mortality; multiple myeloma; myeloma; observational study; open study; overall survival; progression free survival; retrospective study; seizure; single drug dose; transplantation conditioning; treatment response; autotransplantation; chromosome analysis; disease free survival; hematopoietic stem cell transplantation; multiple myeloma

Campos de Estudio

Cita

Compartir